A recent study established high sensitivity and specificity for three CLIA waived point-of-care molecular flu tests in pediatric samples.
The firm is developing the test under a contract with the US Department of Health and Human Services' Biomedical Advanced Research and Development Authority.
The firm saw a 36 percent increase in influenza product sales compared to the third quarter last year.
Cambridge, UK-based Sense Biodetection will use the funding to develop a portfolio of instrument-free, point-of-care molecular diagnostic tests.
The test is the latest in a series of CE-IVD-marked assays the company has launched for use on Becton Dickinson's PCR-based BD Max platform.
Investigators at the Foundation for Research and Technology - Hellas, a Greek research institute, are coordinating the effort.
The company's Acucy Influenza A&B test detects viral nucleoprotein antigens from nasal and nasopharyngeal swabs.
Beyond its HostDx Sepsis test, the firm is working on a test to detect and differentiate bacterial from viral infections in patients presenting with fever.
The company said it is pushing to begin simultaneous clinical trials for multiple small panel-based tests for its sample-to-answer Savanna platform.
The firm experienced a 30 percent jump in sales of immunoassays, attributed in part to a $6.2 million increase in influenza revenues year-over-year.